We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Telix Radiopharmaceutical Production Facility Buildout Commences MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX...
EAU Updates Guidance for PSMA-PET Imaging MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:...
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix...
First Patient Dosed in ProstACT Program for Prostate Cancer Therapy MELBOURNE, Australia, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company...
Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA MELBOURNE, Australia and LIÈGE Belgium, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix® MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the...
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited...
Australian TGA Approves Illuccix® for Prostate Cancer Imaging MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.04 | -4.47311827957 | 23.25 | 23.36 | 22.03 | 835106 | 22.95232325 | DE |
4 | 1.17 | 5.5608365019 | 21.04 | 23.99 | 20.51 | 947575 | 22.23304589 | DE |
12 | 2.15 | 10.7178464606 | 20.06 | 23.99 | 17.03 | 1090264 | 20.38867178 | DE |
26 | 6.82 | 44.3144899285 | 15.39 | 23.99 | 14.42 | 1356579 | 19.14755902 | DE |
52 | 12.65 | 132.322175732 | 9.56 | 23.99 | 9.03 | 1180289 | 16.17307078 | DE |
156 | 15.06 | 210.629370629 | 7.15 | 23.99 | 3.55 | 1156205 | 10.54269612 | DE |
260 | 20.38 | 1113.66120219 | 1.83 | 23.99 | 0.755 | 971970 | 8.3904692 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions